These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28502299)

  • 21. Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress.
    Zhai B; Hu F; Yan H; Zhao D; Jin X; Fang T; Pan S; Sun X; Xu L
    PLoS One; 2015; 10(9):e0138485. PubMed ID: 26381511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of the β-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells.
    Lin YT; Chao CC
    Oncotarget; 2015 Nov; 6(36):38999-9017. PubMed ID: 26517516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma.
    Deng YR; Liu WB; Lian ZX; Li X; Hou X
    Oncotarget; 2016 Jun; 7(25):38292-38305. PubMed ID: 27203677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma.
    Tomonari T; Takeishi S; Taniguchi T; Tanaka T; Tanaka H; Fujimoto S; Kimura T; Okamoto K; Miyamoto H; Muguruma N; Takayama T
    Oncotarget; 2016 Feb; 7(6):7207-15. PubMed ID: 26769852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.
    D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1237-1245. PubMed ID: 25907508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR‑378a enhances the sensitivity of liver cancer to sorafenib by targeting VEGFR, PDGFRβ and c‑Raf.
    Fu H; Zhang J; Pan T; Ai S; Tang L; Wang F
    Mol Med Rep; 2018 Mar; 17(3):4581-4588. PubMed ID: 29328399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Trametenolic acid inhibits migration and invasion of hepatocellular carcinoma HepG2.2.15 cells via RhoC/ROCK1 pathway].
    Wan YL; Wang JZ; Yuan Y; Ye WY; Li HL; Zhang XL; Zhang HQ; Li LE
    Zhongguo Zhong Yao Za Zhi; 2024 Jan; 49(1):185-196. PubMed ID: 38403351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
    Zhang W; Liu S; Liu K; Ji B; Wang Y; Liu Y
    Oncol Rep; 2014 Nov; 32(5):1913-22. PubMed ID: 25176394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.
    Serova M; Tijeras-Raballand A; Dos Santos C; Albuquerque M; Paradis V; Neuzillet C; Benhadji KA; Raymond E; Faivre S; de Gramont A
    Oncotarget; 2015 Aug; 6(25):21614-27. PubMed ID: 26057634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression.
    Hsieh SC; Tsai JP; Yang SF; Tang MJ; Hsieh YH
    Amino Acids; 2014 Dec; 46(12):2809-22. PubMed ID: 25245054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
    Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
    Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion.
    Sprinzl MF; Puschnik A; Schlitter AM; Schad A; Ackermann K; Esposito I; Lang H; Galle PR; Weinmann A; Heikenwälder M; Protzer U
    J Hepatol; 2015 Apr; 62(4):863-70. PubMed ID: 25463538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
    Peng S; Wang Y; Peng H; Chen D; Shen S; Peng B; Chen M; Lencioni R; Kuang M
    Hepatology; 2014 Oct; 60(4):1264-77. PubMed ID: 24849467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liposomal clodronate combined with Cisplatin or Sorafenib inhibits hepatocellular carcinoma cell proliferation, migration and invasion by suppressing FOXQ1 expression.
    Zhou Y; Chen Y; Ma C; Shao B; Zhang F
    Cell Mol Biol (Noisy-le-grand); 2020 Apr; 66(1):49-54. PubMed ID: 32359383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of GnT-V knockdown on the proliferation, migration and invasion of the SMMC7721/R human hepatocellular carcinoma drug-resistant cell line.
    Li B; Su S; Zhang MY; He L; Wang QD; He K
    Mol Med Rep; 2016 Jan; 13(1):469-76. PubMed ID: 26531171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy.
    Prieto-Domínguez N; Ordóñez R; Fernández A; Méndez-Blanco C; Baulies A; Garcia-Ruiz C; Fernández-Checa JC; Mauriz JL; González-Gallego J
    J Pineal Res; 2016 Oct; 61(3):396-407. PubMed ID: 27484637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Notch1 downregulation combined with interleukin-24 inhibits invasion and migration of hepatocellular carcinoma cells.
    Han B; Liu SH; Guo WD; Zhang B; Wang JP; Cao YK; Liu J
    World J Gastroenterol; 2015 Sep; 21(33):9727-35. PubMed ID: 26361419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nemorosone inhibits the proliferation and migration of hepatocellular carcinoma cells.
    Frión-Herrera Y; Gabbia D; Cuesta-Rubio O; De Martin S; Carrara M
    Life Sci; 2019 Oct; 235():116817. PubMed ID: 31476309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KIAA1429 mediates epithelial mesenchymal transition in sorafenib-resistant hepatocellular carcinoma through m6A methylation modification.
    Kuang Y; Cheng Y; Wang J; Li H; Cao X; Wang Y
    Cancer Med; 2023 Mar; 12(6):7222-7233. PubMed ID: 36420693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.